Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics
Seminars in Cancer Biology · 2026-01 · 118 · 62-73
DOI: 10.1016/j.semcancer.2025.12.002 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Seminars in Cancer Biology, 2026-01. Verfasst von Dongliang Wei und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and maxillofacial Head and neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shan…. Hauptthemen laut MEDLINE: Neoplasms, Immunotherapy, Precision Medicine, Microbiota. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 110 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Jiao Tong University.
Abstract (Originalsprache)
The microbiota has emerged as a pivotal modulator of cancer immunotherapy, offering novel insights into the efficacy and toxicity of immune checkpoint inhibitors (ICIs). Recent evidence highlights that microbial communities and their metabolites dynamically regulate host immunity by priming dendritic cells, enhancing T-cell infiltration, and reprogramming the tumor microenvironment. Microbiome dysbiosis is implicated in immune-related adverse events (irAEs), underscoring its dual role in therapeutic outcomes. Leveraging these findings, precision microbiome interventions, including fecal microbiota transplantation, engineered probiotics, and dietary modulation, which demonstrate potential to enhance ICIs responsiveness and mitigate irAEs in preclinical and early-phase clinical studies. However, translating these strategies into clinical practice requires rigorous validation through multicenter trials to establish safety, efficacy, and standardized protocols. This review synthesizes current knowledge on the microbiome-immune-oncology axis, with a focus on mechanistic underpinnings, translational challenges, and innovative therapeutic strategies. By integrating microbiome profiling with patient-specific factors, proposing a roadmap for personalized immunotherapy, aligning with the emerging paradigm of precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and maxillofacial Head and neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200001, PR China; College of Stomatology, Shanghai Jiao Tong Univ…
Förderung
- National Natural Science Foundation of China
- Shanghai Jiao Tong University
Zitieren
APA
Wei, D., Sun, Y., Han, J., & Liu, J. (2026). Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics. Seminars in Cancer Biology, 118, 62-73. https://doi.org/10.1016/j.semcancer.2025.12.002
Vancouver
Wei D, Sun Y, Han J, Liu J. Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics. Seminars in Cancer Biology. 2026;118:62-73. doi:10.1016/j.semcancer.2025.12.002
BibTeX
@article{Wei2026,
author = {Wei, Dongliang and Sun, Yilan and Han, Jing and Liu, Jiannan},
title = {Microbiota and cancer immunotherapy: Mechanisms, clinical implications, and precision therapeutics},
journal = {Seminars in Cancer Biology},
year = {2026},
volume = {118},
pages = {62--73},
doi = {10.1016/j.semcancer.2025.12.002}
}
EUVIMED